Aptevo TherapeuticsAPVO
13F holders, Q1 2026 (March 31)9holders −2
2new positions
5sold out
$4.27avg. 13F price*
At the end of Q1 2026, 9 institutions reported holding Aptevo Therapeutics Inc. (APVO) in their 13F filings, down 2 from Q4 2025. 2 opened new positions and 5 sold out. The largest holders were Gsa Capital Partners LLP ($84K), Geode Capital Management, LLC ($57K) and Vanguard Capital Management LLC ($54K).
- Company
- Aptevo Therapeutics Inc.
- CUSIP
- 03835L702
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $141K |
| Exits | 5 | $27K |
All 13F filers, Q4 2025 → Q1 2026: 36,328 shares bought and 2,876 shares sold, net +33,452 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Gsa Capital Partners LLP | 0.01% | New | 19,638 | $84K |
| Geode Capital Management, LLC | 0.00% | New | 13,337 | $57K |
| Vanguard Capital Management LLC | 0.00% | — | 12,713 | $54K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 4,142 | $18K |
| UBS Group AG | 0.00% | Add +1926.5% | 3,445 | $15K |
| Osaic Holdings, Inc. | 0.00% | No change | 360 | $2K |
| SBI Securities Co., Ltd. | 0.00% | Add +251.6% | 109 | $465 |
| Cwm, LLC | 0.00% | Reduce -16.7% | 5 | $21 |
| Danske Bank A/S | 0.00% | No change | 1 | $4 |
"% of holder's portfolio" is APVO's weight in each manager's 13F, not the share of Aptevo Therapeutics Inc. the manager owns.